[Accepted Manuscript] Snapshot profiling of anti-leishmanial potency of lead compounds and drug candidates against intracellular L. donovani amastigotes with focus on human derived host cells.

Koniordou, M.; Patterson, S.; Wyllie, S.; Seifert, K.; (2017) [Accepted Manuscript] Snapshot profiling of anti-leishmanial potency of lead compounds and drug candidates against intracellular L. donovani amastigotes with focus on human derived host cells. Antimicrobial agents and chemotherapy. ISSN 0066-4804 DOI: https://doi.org/10.1128/AAC.01228-16

Abstract

This study characterised in vitro potencies of anti-leishmanial agents against intracellular Leishmania donovani amastigotes in primary human macrophages, obtained with or without CD14-positive monocyte enrichment, phorbol 12-myristate 13-acetate (PMA) differentiated THP-1 cells and mouse peritoneal exudate macrophages (PEMs). Host cell dependent potency was confirmed for pentavalent and trivalent antimony. Fexinidazole was inactive against intracellular amastigotes across the host cell panel. Fexinidazole sulfone, (R)-PA-824, (S)-PA-824 and VL-2098 displayed similar potency in all host cells tested.

Additional Information

Item Type	Article
Faculty and Department	Faculty of Infectious and Tropical Diseases > Department of Infection Biology > Dept of Immunology and Infection (-2019)